XTL Biopharmaceuticals Ltd
XTLB
Company Profile
Business description
XTL Biopharmaceuticals Ltd is an intellectual property-based company focused on the development, management, and commercialization of intellectual property. The Company is engaged in biotechnology through its subsidiary Psyga Bio and in the biopharmaceutical industry with hCDR1, a novel compound working via a novel mechanism of action for the treatment of Systemic Lupus Erythematosus (SLE) and a potential treatment for Sjogren's syndrome (SS). It focuses on the acquisition and development of proprietary products and late-stage pharmaceutical product candidates for the treatment of unmet clinical needs.
Contact
85 Medinat Hayehudim Street
Hertzlia4676670
ISRT: +972 542288897
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
5
Stocks News & Analysis
stocks
SpaceX is scaling AI infrastructure on earth, data centers in space might be next
Our view on the first results as a publicly traded company.
stocks
A look into newly listed Glencore’s valuation
A new ASX heavyweight with coal, copper and trading exposure.
stocks
Meta is up 9% this year. Is it still a buy ahead of earnings?
We’ll be watching Muse agent adoption, revenue growth, and more.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,956.60 | 12.40 | 0.14% |
| CAC 40 | 7,916.78 | 78.29 | 1.00% |
| DAX 40 | 25,680.75 | 376.33 | 1.49% |
| Dow JONES (US) | 52,464.14 | 31.74 | -0.06% |
| FTSE 100 | 10,768.47 | 35.47 | 0.33% |
| HKSE | 23,651.87 | 215.87 | -0.90% |
| NASDAQ | 26,616.18 | 191.36 | 0.72% |
| Nikkei 225 | 64,621.24 | 545.82 | 0.85% |
| NZX 50 Index | 13,761.29 | 129.60 | 0.95% |
| S&P 500 | 7,727.86 | 15.29 | 0.20% |
| S&P/ASX 200 | 8,831.30 | 14.40 | 0.16% |
| SSE Composite Index | 3,713.03 | 22.34 | -0.60% |